Alps Advisors Inc Bellus Health Inc. Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$7.14 - $8.53 $12,523 - $14,961	-1,754 Reduced 2.06%	83,199 $599,000
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $136,271 - $178,379	16,578 Added 24.25%	84,953 $698,000
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $41,868 - $56,136	4,678 Added 7.34%	68,375 $722,000
Q2 2022 Aug 11, 2022	SELL	$6.46 - $10.02 $297,263 - $461,080	-46,016 Reduced 41.94%	63,697 $589,000
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $103,499 - $148,733	18,615 Added 20.43%	109,713 $755,000
Q4 2021 Feb 09, 2022	BUY	$5.26 - $8.3 $479,175 - $756,113	91,098 New	91,098 $733,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.